Table 1.
Clinical and demographic characteristics.
| All patients | Completers | Non-completersa | Test statisticb | p-valueb | |
|---|---|---|---|---|---|
| Sample size | N = 28 | n = 20 | n = 8 | – | – |
| Diagnoses, No. (%) | Fisher’s exact | p = 1.000 | |||
| Schizophrenia (SZ) | 6 (21.4%) | 4 (20.0%) | 2 (25.0%)a | – | – |
| Schizoaffective disorder (SZA) | 12 (42.9%) | 9 (45.0%) | 3 (37.5%) | – | – |
| Psychotic bipolar disorder (BD) | 10 (35.7%) | 7 (35.0%) | 3 (37.5%)a | – | – |
| Age, mean ± SD (range), y | 31.8 ± 7.6 (19–48) | 31.9 ± 7.8 (19–48) | 31.6 ± 7.4 (23–42) | t = −0.0698 | p = 0.945 |
| Female, No. (%) | 13 (46.4%) | 10 (50%) | 3 (37.5%) | Fisher’s exact | p = 0.686 |
| Race/Ethnicity | Fisher’s exact | p = 0.643 | |||
| White, Non-Hispanic | 21 (75.0%) | 15 (75.0%) | 6 (75.0%) | – | – |
| White, Hispanic/Latino | 1 (3.6%) | 1 (5.0%) | 0 (0.0%) | – | – |
| Black/African-American | 2 (7.1%) | 2 (10.0%) | 0 (0.0%) | – | – |
| Asian | 3 (10.7%) | 1 (5.0%) | 2 (25.0%) | – | – |
| Mixed | 1 (3.6%) | 1 (5.0%) | 0 (0.0%) | – | – |
| Completed education, No. (%) | Fisher’s exact | p = 0.154 | |||
| High school/GED | 6 (21.4%) | 6 (30.0%) | 0 (0.0%) | – | – |
| Part-college or 2 years college | 10 (35.7%) | 8 (40.0%) | 2 (25.0%) | – | – |
| College/bachelor’s degree | 8 (28.6%) | 4 (20.0%) | 4 (50.0%) | – | – |
| Graduate/professional school | 4 (14.3%) | 2 (10.0%) | 2 (25.0%) | – | – |
| Estimated IQc, mean ± SD | |||||
| Verbal IQ | 118.3 ± 10.4 | 116.5 ± 10.8 | 122.9 ± 8.2 | t = 1.3995 | p = 0.175 |
| Performance IQ | 114.5 ± 4.9 | 113.6 ± 5.1 | 116.6 ± 3.9 | t = 1.4009 | p = 0.175 |
| Full scale IQ | 118.7 ± 9.1 | 117.1 ± 9.5 | 122.7 ± 7.2 | t = 1.3998 | p = 0.175 |
| PANSS total score, mean ± SD | 41.0 ± 27.3 | 45.5 ± 23.6 | 29.9 ± 34.1 | t = −1.3939 | p = 0.175 |
| Positive | 9.8 ± 7.3 | 11.1 ± 6.9 | 6.5 ± 7.7 | t = −1.5341 | p = 0.137 |
| Negative | 10.4 ± 7.3 | 11.4 ± 6.5 | 8.0 ± 9.0 | t = −1.1145 | p = 0.275 |
| General psychopathology | 20.9 ± 13.5 | 23.1 ± 11.2 | 15.4 ± 17.6 | t = −1.3834 | p = 0.178 |
| PSYRATS-AH, mean ± SD | 4.1 ± 9.4 | 4.3 ± 9.3 | 3.6 ± 10.3 | t = −0.1690 | p = 0.867 |
| YMRS, mean ± SD | 7.3 ± 9.3 | 7.6 ± 9.8 | 6.6 ± 8.8 | t = −0.2326 | p = 0.818 |
| MADRS, mean ± SD | 10.9 ± 11.2 | 12.8 ± 11.2 | 6.3 ± 10.4 | t = −1.4136 | p = 0.169 |
| CPZ equivalent dose, mean ± SD (range), mg/day | 242.4 ± 311.6 (0–1,200) | 251.7 ± 317.3 (0–1,200) | 219.3 ± 316.9 (0–900) | t = −0.2437 | p = 0.809 |
| Taking antipsychotic drug | 17 (60.7%) | 12 (60.0%) | 5 (62.5%) | ||
| Taking mood stabilizer | 14 (50.0%) | 10 (50.0%) | 4 (50.0%) | ||
| Taking either antipsychotic or mood stabilizer | 23 (82.1%) | 17 (85.0%) | 6 (75.0%) | ||
| Not taking any psychotropic drug | 4 (14.3%) | 3 (15.0%) | 1 (12.5%) | ||
Two non-completers either withdrew (1 BD) or were excluded (1 SZ) prior to TBS randomization and do not contribute any results data.
Test statistics and p-values are from a comparison of completers vs. non-completers, using a significance threshold of p < 0.05. All t-tests are 2-sided.
Estimated intelligence quotient (IQ) estimated using the North American Adult Reading Test (NAART); NAART data are missing from 3 patients (2 completers, 1 non-completer).
GED, general educational development test; IQ, intelligence quotient; PANSS, positive and negative syndrome scale; PSYRATS-AH, psychotic symptom rating scale, auditory hallucinations subscale; YMRS, Young mania rating scale; MADRS, montgomery-asberg depression rating scale; CPZ, chlorpromazine.